|
(2) In a 6-week, placebo-controlled trial (n= 253) involving 3 fixed dose ranges of olanzapine (5.0 ± 2.5 mg/ day, 10.0 ± 2.5 mg/ day, and 15.0 ± 2.5 mg/ day) on a once daily schedule, the two highest olanzapine dose groups (actual mean doses of 12 and 16 mg/ day, respectively) were superior to placebo on BPRS total score, BPRS psychosis cluster, and CGI severity score; the
highest olanzapine dose group was superior to placebo on the SANS. There was no clear advantage for the high dose group over the medium dose group. Examination of population subsets (race and gender) did not reveal any differential responsiveness on the basis of these subgroupings. In a longer-term trial, adult outpatients (n= 326) who predominantly met DSM-IV criteria for schizophrenia and who remained stable on olanzapine during open label treatment for at least 8 weeks were randomized to continuation on their current olanzapine doses (ranging from 10 to 20 mg/ day) or to placebo. The follow-up period to observe patients for relapse, defined in terms of increases in BPRS positive symptoms or hospitalization, was planned for 12 months, however, criteria were met for stopping the trial early due to an excess of placebo relapses compared to olanzapine relapses, and olanzapine was superior to placebo on time to relapse, the primary outcome for this study. Thus, olanzapine was more effective than placebo at maintaining efficacy in patients stabilized for approximately 8 weeks and followed for an observation period of up to 8 months. Bipolar Disorder Monotherapy — The efficacy of olanzapine in the treatment of acute manic or mixed episodes was established in 2 short-term (one 3-week and one 4-week) placebo-controlled trials in patients who met the DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes. These trials included patients with or without psychotic features and with or without a rapid-cycling course. The primary rating instrument used for assessing manic symptoms in these trials was the Young Mania Rating Scale (Y-MRS), an 11-item clinician-rated scale traditionally used to assess the degree of manic symptomatology (irritability, disruptive/ aggressive behavior, sleep, elevated mood, speech, increased activity, sexual interest, language/ thought disorder, thought content, appearance, and insight) in a range from 0 (no manic features) to 60 (maximum score). The primary outcome in these trials was change from baseline in the Y-MRS total score. The results of the trials follow: Text Continues Below
(1) In one 3-week placebo-controlled trial (n= 67) which involved a dose range of olanzapine (5-20 mg/ day, once daily, starting at 10 mg/ day), olanzapine was superior to placebo in the reduction of Y-MRS total score. In an identically designed trial conducted simultaneously with the first trial, olanzapine demonstrated a similar treatment difference, but possibly due to sample size and site variability, was not shown to be superior to placebo on this outcome. (2) In a 4-week placebo-controlled trial (n= 115) which involved a dose range of olanzapine (5-20 mg/ day, once daily, starting at 15 mg/ day), olanzapine was superior to placebo in the reduction of Y-MRS total score.
(3) In another trial, 361 patients meeting DSM-IV criteria for a manic or mixed episode of bipolar disorder who had responded during an initial open-label treatment phase for about two weeks, on average, to olanzapine 5 to 20 mg/ day were randomized to either continuation of olanzapine at their same dose (n= 225) or to placebo (n= 136), for observation of relapse.
Approximately 50% of the patients had discontinued from the olanzapine group by day 59 and 50% of the placebo group had discontinued by day 23 of double-blind treatment. Response during the open-label phase was defined by having a decrease of the Y-MRS total score to 12 and HAM-D 21 to 8. Relapse during the double-blind phase was defined as an increase of the Y-MRS or HAM-D 21 total score to 15, or being hospitalized for either mania or depression. In the randomized phase, patients receiving continued olanzapine experienced a significantly longer time to relapse. Combination Therapy — The efficacy of olanzapine with concomitant lithium or valproate in the treatment of acute manic episodes was established in two controlled trials in patients who met the DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes. These trials included patients with or without psychotic features and with or without a rapid-cycling course. The results of the trials follow: (1) In one 6-week placebo-controlled combination trial, 175 outpatients on lithium or valproate therapy with inadequately controlled manic or mixed symptoms (Y-MRS 16) were randomized to receive either olanzapine or placebo, in combination with their original therapy. Olanzapine (in a dose range of 5-20 mg/ day, once daily, starting at 10 mg/ day) combined with lithium or valproate (in a therapeutic range of 0.6 mEq/ L to 1.2 mEq/ L or 50 µ g/ mL to 125 µ g/ mL, respectively) was superior to lithium or valproate alone in the reduction of Y-MRS total score. (2) In a second 6-week placebo-controlled combination trial, 169 outpatients on lithium or valproate therapy with inadequately controlled manic or mixed symptoms (Y-MRS 16) were randomized to receive either olanzapine or placebo, in combination with their original therapy. Olanzapine (in a dose range of 5-20 mg/ day, once daily, starting at 10 mg/ day) combined with lithium or valproate (in a therapeutic range of 0.6 mEq/ L to 1.2 mEq/ L or 50 µ g/ mL to 125 µ g/ mL, respectively) was superior to lithium or valproate alone in the reduction of Y-MRS total score. Page: << Prev | 1 | 2 | 3 | 4 | 5
|
.gif)
